Impact Factor 3.845 | CiteScore 3.92
More on impact ›

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2019.01426

A preliminary, multicenter, prospective and real world study on the hemostasis, coagulation, and safety of Hemocoagulase Atrox in patients undergoing transurethral bipolar plasmakinetic prostatectomy

 Bing-Hui Li1,  Zhao-Jun Yu2,  Chao-Yang Wang3, Hao Zi1, 3, 4, Xiao-Dong Li3, 4,  Xing-Huan Wang1, Xuan-Yi Ren5, Tong-Zu Liu1 and Hang Zheng1*
  • 1Department of Urology, Zhongnan Hospital of Wuhan University, China
  • 2Graduate School, Nanchang University, China
  • 3Center for Evidence-Based Medicine, Institute of Evidence-Based Medicine and Knowledge Translation, Henan University, China
  • 4Department of Urology, Huaihe Hospital of Henan University, China
  • 5Department of Urology, Kaifeng Central Hospital, China

Objective: To evaluate the hemostasis and coagulation effect of Hemocoagulase Atrox in benign prostatic hyperplasia (BPH) patients undergoing transurethral bipolar plasmakinetic prostatectomy (TUPKP).
Methods: This study adopted a multicenter, prospective, and real world design. BPH patients undergoing TUPKP were divided into two groups according to whether they adopted Hemocoagulase Atrox (group B) or not (group A) during perioperative period. The electronic clinical data on every included subject, including the international prostate symptom score (IPSS) and the quality of life scale (QoL), maximum urinary flow rate (Qmax), complete blood count, coagulation screening test and adverse events, were measured and compared between the two groups.
Results: Finally, 695 patients, 443 in Group A and 252 in group B, were included. Baseline characteristics showed no significant difference between two groups. In group A, compared with baseline, IPSS decreased by 15.66 (95% CI = -16.45 ~ -14.87), QoL decreased by 3.08 (95% CI = -3.30 ~ -2.87), prothrombin time prolonged by 1.02 s (95% CI = 0.56 ~ 1.48), while white blood cells, neutrophils and lymphocytes also significantly changed; white blood cells, neutrophils and platelets increased, while lymphocytes decreased by 0.14×109/L (95% CI = -0.21 ~ -0.08) before discharge. In group B, IPSS decreased by 16.12 (95% CI= -17.02 ~-15.21), QoL decreased by 3.32 (95% CI= -3.56 ~ -3.07), and white blood cells, neutrophils and lymphocytes were also significantly changed, along with white blood cells and lymphocytes that tested before discharge (P< 0.001). After adjustment, transfusion risk was similar in the two groups (OR = 1.582, 95%CI= 0.552 ~ 4.538). Parameters had no substantial difference between the two subgroups whether prostate volume was more than 80 ml or not.
Conclusion: Hemocoagulase Atrox is probably safe among BPH patients undergoing TUPKP, exhibiting fine hemostasis and coagulation efficacy, and would not be influenced by prostate volume.

Keywords: Benign prostatic hyperplasia, Transurethral bipolar plasmakinetic prostatectomy, Hemocoagulase Atrox, Hemostasis, Blood Transfusion, Coagulation, Real world study

Received: 10 Sep 2019; Accepted: 08 Nov 2019.

Copyright: © 2019 Li, Yu, Wang, Zi, Li, Wang, Ren, Liu and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: MD, PhD. Hang Zheng, Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei Province, China,